Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Well Positioned For US Drug Pricing Changes Regardless Of Timing Or Form, Duato Says

Executive Summary

Boasting of 14 current or near-term blockbusters and success staving off Remicade biosimilars, Johnson & Johnson says its growth derives 100% from sales volume, not price increases. All the same, it continues call for slow pricing reform.

Advertisement

Related Content

As J&J Sees Continued Drug Price Declines, CEO Urges Slow Policy Change Via Trump's Blueprint
Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model
J&J Stays Within Price Pledge, But Average Doesn't Tell The Whole Story, Analyst Says
Exclusive Remicade Contracts Are Slowing Biosimilar Uptake
Janssen's Drug Pricing Report Emphasizes Value Of Rebates
J&J’s $30bn For Actelion Buys Immediate And Longer-Term Value
Fresh From The White House, J&J's Gorsky Talks Policy, Drug Pricing

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123835

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel